You are here: Home Welcome Q3 Report 2018 Filgotinib, a selective JAK1-inhibitor which has shown activity and favorable tolerability in inflammatory diseases. Financial highlights Group revenues €205.1 million Read more Cash position €1343.7 million Read more Letter from the management This quarter has been a particularly exciting one for Galapagos, and quite a historical one for our company. Read more
